| scholarly article | Q13442814 |
| P50 | author | Susan M. Ramin | Q110252023 |
| P2093 | author name string | Yang Xia | |
| Yujin Zhang | |||
| M John Hicks | |||
| Rodney E Kellems | |||
| Roxanna A Irani | |||
| Sean C Blackwell | |||
| Cissy Chenyi Zhou | |||
| P2860 | cites work | Biological functions of angiotensin and its receptors | Q28306268 |
| Tumor necrosis factor induces glomerular damage in the rabbit | Q33444321 | ||
| The detrimental role of angiotensin receptor agonistic autoantibodies in intrauterine growth restriction seen in preeclampsia | Q33591058 | ||
| TNF-alpha inhibition reduces renal injury in DOCA-salt hypertensive rats | Q33647618 | ||
| Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia: correlation with disease severity | Q33748680 | ||
| Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor | Q33848380 | ||
| Pathogenesis and genetics of pre-eclampsia | Q33934445 | ||
| Human pro-tumor necrosis factor is a homotrimer | Q34386603 | ||
| Latest advances in understanding preeclampsia | Q34425288 | ||
| Angiotensin II induces soluble fms-Like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy | Q35699115 | ||
| Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice | Q35701236 | ||
| Immunosuppressive treatment protects against angiotensin II-induced renal damage | Q35747734 | ||
| Endothelin, the kidney, and hypertension | Q36554955 | ||
| The role of the immune system in preeclampsia | Q36791219 | ||
| NK cells and pre-eclampsia | Q36812227 | ||
| Experimental elimination of tumor necrosis factor in low-dose endotoxin models has variable effects on survival | Q36966855 | ||
| Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction | Q37022723 | ||
| Inflammatory cytokines in the pathophysiology of hypertension during preeclampsia | Q37119326 | ||
| Cellular localization of AT1 receptor mRNA and protein in normal placenta and its reduced expression in intrauterine growth restriction. Angiotensin II stimulates the release of vasorelaxants | Q37377636 | ||
| Hypertension in response to chronic reductions in uterine perfusion in pregnant rats: effect of tumor necrosis factor-alpha blockade | Q37459545 | ||
| Vasoactive peptides and uterine vessels | Q40383652 | ||
| Angiotensin receptor subtype AT(1) mediates alveolar epithelial cell apoptosis in response to ANG II. | Q40746660 | ||
| Interleukin-12 augments cytolytic activity of peripheral and decidual lymphocytes against choriocarcinoma cell lines and primary culture human placental trophoblasts | Q40946626 | ||
| Angiotensin II induces apoptosis in human and rat alveolar epithelial cells | Q40954053 | ||
| Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions | Q41355139 | ||
| Placental cytokines and the pathogenesis of preeclampsia | Q41452017 | ||
| Angiotensin II signal transduction in vascular smooth muscle: role of tyrosine kinases | Q41454874 | ||
| Angiotensin II induces tumor necrosis factor biosynthesis in the adult mammalian heart through a protein kinase C-dependent pathway | Q43982318 | ||
| Differential effects between marimastat, a TNF-alpha converting enzyme inhibitor, and anti-TNF-alpha antibody on murine models for sepsis and arthritis | Q44025492 | ||
| TNF-alpha enhances contraction and inhibits endothelial NO-cGMP relaxation in systemic vessels of pregnant rats | Q44031650 | ||
| Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. | Q44201217 | ||
| Autoantibody against AT1 receptor from preeclamptic patients induces vasoconstriction through angiotensin receptor activation | Q44218760 | ||
| Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human trophoblast cells | Q44320558 | ||
| AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase | Q44385661 | ||
| Angiotensin II-induced MMP-2 release from endothelial cells is mediated by TNF-alpha | Q44673765 | ||
| Antibodies from preeclamptic patients stimulate increased intracellular Ca2+ mobilization through angiotensin receptor activation | Q45069619 | ||
| Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human mesangial cells and induce interleukin-6 and plasminogen activator inhibitor-1 secretion | Q46344658 | ||
| Protein kinase-mediated regulation of calcineurin through the phosphorylation of modulatory calcineurin-interacting protein 1. | Q46895776 | ||
| Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 synthesis. | Q47909651 | ||
| Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia | Q47915288 | ||
| Cytotoxicity of tumour necrosis factor-alpha and gamma-interferon against primary human placental trophoblasts. | Q50767140 | ||
| Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. | Q51037240 | ||
| Raised serum TNF-alpha, blood sugar and uric acid in preeclampsia in third trimester of pregnancy. | Q51501322 | ||
| Evidence for a role of tumor necrosis factor alpha in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease. | Q51572038 | ||
| Role of endothelin in mediating tumor necrosis factor-induced hypertension in pregnant rats. | Q54661322 | ||
| Evidence for an elevation in serum interleukin-2 and tumor necrosis factor-alpha levels before the clinical manifestations of preeclampsia | Q73628337 | ||
| AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor | Q73815485 | ||
| Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy | Q74090763 | ||
| Angiotensin II induces TNF production by the thick ascending limb: functional implications | Q74154109 | ||
| Definitive molecular evidence of renin-angiotensin system in human uterine decidual cells | Q74188076 | ||
| Circulating levels of immunoreactive cytokines in women with preeclampsia | Q77384781 | ||
| Angiotensin II decreases system A amino acid transporter activity in human placental villous fragments through AT1 receptor activation | Q79760387 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | autoantibody | Q785022 |
| pre-eclampsia | Q61335 | ||
| P304 | page(s) | 1246-1253 | |
| P577 | publication date | 2010-03-29 | |
| P1433 | published in | Hypertension | Q5958695 |
| P1476 | title | Autoantibody-mediated angiotensin receptor activation contributes to preeclampsia through tumor necrosis factor-alpha signaling | |
| P478 | volume | 55 |
| Q28069689 | A Dormant Microbial Component in the Development of Preeclampsia |
| Q27003069 | A leading role for the immune system in the pathophysiology of preeclampsia |
| Q34870775 | A2B adenosine receptor-mediated induction of IL-6 promotes CKD. |
| Q38118625 | Activating autoantibodies and cardiovascular disease |
| Q64111458 | Angiotensin II type i receptor agonistic autoantibodies induces apoptosis of cardiomyocytes by downregulating miR21 in preeclampsia: a mechanism study |
| Q27027039 | Angiotensin receptor agonistic autoantibodies and hypertension: preeclampsia and beyond |
| Q37816496 | Animal models of pre-eclampsia. |
| Q26828588 | Antibodies in the pathogenesis of hypertension |
| Q107324240 | Autoantibodies against ACE2 and angiotensin type-1 receptors increase severity of COVID-19 |
| Q35715914 | Autoantibody-mediated IL-6-dependent endothelin-1 elevation underlies pathogenesis in a mouse model of preeclampsia |
| Q34040357 | Autoantibody-mediated complement C3a receptor activation contributes to the pathogenesis of preeclampsia |
| Q36334105 | Beneficial effect of human umbilical cord-derived mesenchymal stem cells on an endotoxin-induced rat model of preeclampsia |
| Q45020552 | Differential regulation of TNF receptors in maternal leukocytes is associated with severe preterm preeclampsia |
| Q36836373 | Elevated Transglutaminase Activity Triggers Angiotensin Receptor Activating Autoantibody Production and Pathophysiology of Preeclampsia |
| Q26852668 | Elucidating immune mechanisms causing hypertension during pregnancy |
| Q33577570 | Endothelial dysfunction induced by antibodies against angiotensin AT1 receptor in immunized rats |
| Q34072217 | Exposure to AT1 receptor autoantibodies during pregnancy increases susceptibility of the maternal heart to postpartum ischemia-reperfusion injury in rats |
| Q34656228 | Foxp3 (-/ATT) polymorphism contributes to the susceptibility of preeclampsia |
| Q35362708 | Full-length human placental sFlt-1-e15a isoform induces distinct maternal phenotypes of preeclampsia in mice |
| Q36380039 | GPCRs as potential therapeutic targets in preeclampsia. |
| Q83799951 | Hypertension in response to AT1-AA: role of reactive oxygen species in pregnancy-induced hypertension |
| Q35029700 | Hypertension in response to placental ischemia during pregnancy: role of B lymphocytes |
| Q37786350 | Immunologic characteristics of preeclampsia, a comprehensive review |
| Q89860687 | Inflammasomes-A Molecular Link for Altered Immunoregulation and Inflammation Mediated Vascular Dysfunction in Preeclampsia |
| Q39198610 | Inflammation, Autoimmunity, and Hypertension: The Essential Role of Tissue Transglutaminase |
| Q26827525 | Inflammation, immunity, and hypertensive end-organ damage |
| Q38543831 | Linking the old and new -- do angiotensin II type 1 receptor antibodies provide the missing link in the pathophysiology of preeclampsia? |
| Q55004295 | Maternal plasma fetuin-A concentration is lower in patients who subsequently developed preterm preeclampsia than in uncomplicated pregnancy: a longitudinal study. |
| Q34495512 | Maternal serum levels of TNF-alpha and IL-6 long after delivery in preeclamptic and normotensive pregnant women |
| Q34140082 | Maternally sequestered therapeutic polypeptides - a new approach for the management of preeclampsia |
| Q50937792 | Mechanism of agonistic angiotensin II type I receptor autoantibody-amplified contractile response to Ang II in the isolated rat thoracic aorta. |
| Q35099504 | Mesenchymal stem cells ameliorate Th1-induced pre-eclampsia-like symptoms in mice via the suppression of TNF-α expression |
| Q54901493 | Molecular Mechanisms of Preeclampsia. |
| Q33891299 | Morphometric evaluation of preeclamptic placenta using light microscopic images |
| Q37451544 | Placental Ischemia and Resultant Phenotype in Animal Models of Preeclampsia |
| Q39136791 | Recent Advances in Immunity and Hypertension |
| Q35707881 | Receptor-activating autoantibodies and disease: preeclampsia and beyond |
| Q35683468 | Recombinant vascular endothelial growth factor 121 attenuates autoantibody-induced features of pre-eclampsia in pregnant mice |
| Q64907090 | Renin-angiotensin system in pre-eclampsia: everything old is new again. |
| Q47546316 | Role and mechanism of AT1-AA in the pathogenesis of HELLP syndrome |
| Q37067705 | Role of agonistic autoantibodies against type-1 angiotensin II receptor in the pathogenesis of retinopathy in preeclampsia |
| Q38014802 | The pathophysiology of preeclampsia involves altered levels of angiogenic factors promoted by hypoxia and autoantibody-mediated mechanisms |
| Q57150158 | The role of Agonistic Autoantibodies to the Angiotensin II Type 1 Receptor (AT1-AA) in Pathophysiology of Preeclampsia |
| Q33834419 | The role of inflammation in the pathology of preeclampsia |
| Q33668328 | The therapeutic potential of antioxidants, ER chaperones, NO and H2S donors, and statins for treatment of preeclampsia |
| Q48284671 | Therapeutic benefit of mesenchymal stem cells in pregnant rats with angiotensin receptor agonistic autoantibody-induced hypertension: Implications for immunomodulation and cytoprotection. |
| Q36836229 | Tumor necrosis factor-α: regulation of renal function and blood pressure |
Search more.